AstraZeneca records 50% share of gross profits on sales of Beyfortus in major markets outside the United States and 25% of ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

Starting November 4, doses of the RSV immunization will also be available for infants and high-risk children up to 24 months ...

BEYFORTUS® Product Monograph, Sanofi Pasteur Limited, June 14, 2024. ii BEYFORTUS® Product Monograph, Sanofi Pasteur Limited, June 14, 2024. iii ...

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Sanofi (SNYNF – Research Report), with a price target of €112.00.

The most recent U.S. Food and Drug Administration inspection of Thermo Fisher’s Greenville plant in May identified manufacturing issues for the respiratory syncytial virus drug Beyfortus, a preventive ...

Q3 2024 Earnings Call Transcript October 25, 2024 Sanofi beats earnings expectations. Reported EPS is $1.57, expectations ...

Beyfortus Sales Projection: Expected to reach around ... Opella Valuation: EUR16 billion EV, 14 times 2024 estimated EBITDA. Sanofi SA (NASDAQ:SNY) reported a strong sales performance with Q3 sales ...

Beyfortus, thanks to the approval of additional production capacity, according to Sanofi. The group benefited from the strength of Dupixent, which treats a number of diseases linked to immune system ...

"Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et ...

With almost EUR3 billion in the first nine months, our launches have become significant contributors to Sanofi's accelerated top line growth profile. Beyfortus leads the way with sales of EUR645 ...